About UMBRELLA Labs
Academic research of orally-bioavailable, nonsteroidal SARMs and peptides has exploded in recent years, spurred by hundreds of promising studies that seek to address a wide variety of indications. Unfortunately, the pace of this research is severely limited by the high prices charged by large chemical companies who have long enjoyed a virtual monopoly on the research market. Umbrella Labs seeks to increase and improve biochemical and molecular biology exploration by lowering research costs, thus removing the barrier for small laboratories to enter into the research space.
The progress of research into selective androgen receptor modulators (SARMs) has been exciting for scientists in a variety of fields. Nonsteroidal SARMs differ from testosterone chiefly due to their inability to convert to active metabolites, such as estradiol and DHT. Additionally, the more favorable pharmacodynamics and AR specificity of nonsteroidal SARMs compared to exogenous testosterone enables more precise pharmacological interactions actions that serve specific roles for preclinical studies.
The inherent tissue selectivity of SARMs as gene expression modulators is due to isoform-specific conformational changes, modulation of surface topology, and discrete protein–protein interactions between AR and other nuclear receptors. Since isoform- and ligand-specific receptor conformation and protein complements differ in each cell type, this ultimately drives tissue-specific gene expression.
Despite the promise of various proteins (e.g., bone morphogenetic protein‐2 (BMP‐2) and platelet‐derived growth factor [PDGF]) as anabolic agents that increase bone formation, many of them are not optimal for therapeutic applications due to their long sequences; this translates into high manufacturing costs, limited supply, and susceptibility to enzymatic degradation as well as side effects outside the skeletal system. Thus, there is a need for inexpensive, novel, short anabolic agents that promote bone formation to effectively treat bone loss associated with aging.
There has been a rapid increase in the study of peptides as potential medications for many diseases. Peptides represent a class of compounds that bind with exquisite specificity to their in vivo targets, resulting in high potencies of action and moderately limited off‐target side effects. Unlike proteins, peptides are smaller in size, more available, and cheaper to manufacture by fully synthetic biochemical methods. The short length of peptides permits their use not only in systemic injections but also as pills or solutions taken orally or sublingually (under the tongue) for bone growth stimulation in clinical research.
UMBRELLA Labs is a USA SARMs supplier that only offers the highest purity, research grade Selective Androgen Receptor Modulators (SARMs) in liquid and powder form for sale.
SARM research provides a platform to design and test molecules that selectively target the androgen receptors in different cell types . The goal of research in this area is to produce a customized response.
When buying SARMs for your research study it is important to choose a USA based supplier that delivers reliable purity, consistently – for this UMBRELLA Labs is your top choice.
This information is for educational purposes only and does not constitute medical advice. THE PRODUCTS DESCRIBED HEREIN ARE FOR RESEARCH USE ONLY. All clinical research must be conducted with oversight from the appropriate Institutional Review Board (IRB). All preclinical research must be conducted with oversight from the appropriate Institutional Animal Care and Use Committee (IACUC) following the guidelines of the Animal Welfare Act (AWA).